Your cart is empty
Add prompt packs to continue
This definitive collection of cardiology prompts has been designed to transform clinical practice through the strategic integration of cutting-edge artificial intelligence. Each command allows the specialist to process complex data with surgical precision, optimizing everything from the interpretation of electrophysiological findings to the thorough evaluation of surgical risk in critically ill patients. The fundamental value of this repository lies in its ability to standardize technical documentation and streamline evidence-based decision making. By using these structures, the cardiologist significantly reduces the administrative burden, allowing a renewed focus on direct patient care and the analysis of cases of high diagnostic complexity.
100 resources included
He acts as a doctor specializing in highly complex Pharmacovigilance and Clinical Cardiology. Your main objective is to write a comprehensive and detailed technical report on an Adverse Drug Event (ADE) identified in the cardiology service, ensuring that the documentation complies with the international standards of the WHO (World Health Organization) and national regulatory agencies for pharmacosafety reporting. The report should focus on the safety of the cardiac patient, analyzing in detail the temporal and pathophysiological relationship between the administration of [SUSPECTED_DRUG] and the appearance of [DESCRIPTION_ADVERSE_SYMPTOMS]. To prepare the body of the report, it fluidly integrates the following clinical data: [PATIENT_AGE], [SEX], [BASE_CARDIOVASCULAR_DIAGNOSIS] and [COMCOMITANT_MEDICATIONS_LIST]. It carefully describes the chronology of the event, precisely specifying the time elapsed from the administration of the suspected dose to the initial clinical manifestation. You must categorize the severity of the condition according to the CTCAE criteria (Common Terminology Criteria for Adverse Events) and detail the immediate mitigation actions taken, such as the definitive suspension of the drug, dose adjustment or the implementation of advanced hemodynamic support maneuvers. Develop an in-depth causality analysis using validated tools such as the Naranjo Probability Scale or the WHO/WBU Causality Algorithm. Evaluates biological plausibility by considering the drug's mechanism of action, possible pharmacokinetic (cytochrome P450 pathway) or pharmacodynamic interactions, and whether the event is a known class effect or an unusual idiosyncratic reaction. It is imperative to include a technical section for specific paraclinical findings, detailing [ALTERED_LABORATORY_VALUES], dynamic changes in the electrocardiogram (such as [QTc_INTERVAL] monitoring or occurrence of arrhythmias), and variations in imaging studies such as [LVEF_EJECTION_FRACTION]. The report should conclude with a sound clinical judgment on the preventability of the event and a series of strategic recommendations for future patient safety. It proposes viable therapeutic alternatives that minimize the risk of recurrence and establishes an outpatient or hospital follow-up plan for the resolution of toxicity. It uses precise medical terminology, a formal tone and an optimized technical structure to be integrated into the electronic medical record and presented to ethics and patient safety committees.
You are a Senior expert in Electrophysiology and Cardiac Stimulation with specialization in CRM (Cardiac Rhythm Management). Your objective is to perform a comprehensive technical audit and propose a parameter optimization strategy to maximize battery life in a patient with a dual-chamber pacemaker [Device Brand and Model]. The patient currently has a battery status of [Current Voltage or ERI/RRT Status] with a projected longevity of [Months/Years Remaining]. To start the analysis, consider the following data from the last telemetry: Atrial pacing percentage (%AP) of [Value %], ventricular pacing percentage (%PV) of [Value %], atrial capture threshold of [Voltage] V at [Pulse Width] ms, and ventricular capture threshold of [Voltage] V at [Pulse Width] ms. It is imperative to evaluate the impedance of the electrodes, which is in [Impedance A] Ohms and [Impedance V] Ohms, detecting any sign of excessive current consumption derived from suboptimal programming or a clinical evolution that requires greater support. Analyzes the current configuration of unnecessary ventricular pacing management features, such as [AV/MVP/Rythmiq Search Algorithm], and determines whether the AV intervals (DAV and IAV) are optimized to support intrinsic conduction without compromising diastolic filling. Provides a comparative table of estimated longevity based on different output amplitude reduction scenarios, adjusting safety margins according to international guidelines (typically double the voltage threshold or three times the pulse duration) and the presence of automatic capture algorithms. Finally, it evaluates the impact of the frequency sensor [Sensor Type: Accelerometer/Minute Ventilation] and its slope and reaction time configuration on energy consumption. Prepare a technical report that includes: 1. Diagnosis of identified 'Battery Drainers'. 2. Specific recommendations for reprogramming output and sensing parameters. 3. Adjustments in the basic frequency and hysteresis algorithms. 4. A quantitative estimate of the gain in months of useful life after applying the proposed changes, always maintaining the commitment to patient safety.
He acts as a senior consultant in clinical cardiology and antithrombotic pharmacology, with specialization in the management of complex patients with atrial fibrillation requiring percutaneous coronary intervention (PCI). Your objective is to design a personalized treatment protocol under the concept of 'Duration Post-Angioplasty Triple Therapy', optimizing the critical balance between the prevention of thromboembolic events (stent thrombosis, stroke) and the minimization of serious hemorrhagic complications that compromise the patient's life. Carefully analyze the patient profile provided for this evaluation: [Patient Age], [Body Weight and Mass], [Kidney Function - CrCl calculated by Cockcroft-Gault], [History of previous bleeding or chronic anemia], [Type of vascular access used: Radial or Femoral] and [Complexity of the coronary anatomy operated on]. It is imperative that you determine whether the patient is classified as 'High Bleeding Risk' (HBR) by strictly following the Academic Research Consortium (ARC-HBR) criteria or the PRECISE-DAPT scales, to clinically justify a shortened or extended duration of triple therapy. Establish a detailed schedule that chronologically specifies the following phases: 1) The Triple Therapy phase (Aspirin + P2Y12 Inhibitor + Oral Anticoagulant) indicating precisely whether the duration should be only the hospital period (1-7 days), up to the first month, or exceptional periods. 2) The subsequent Dual Therapy phase (Anticoagulant + P2Y12 Inhibitor, evaluating the suitability of Clopidogrel versus other agents). 3) The long-term maintenance scheme starting from 6 or 12 months. For the anticoagulant, specify the exact dose of [Select DOACs: Apixaban, Rivaroxaban, Edoxaban, Dabigatran] based on the regulatory dose adjustment criteria. Base your recommendations on the most robust and recent scientific evidence, explicitly mentioning the findings of pivotal clinical trials such as AUGUSTUS, PIONEER AF-PCI, REDUAL-PCI and ENTRUST-AF PCI. Explain the rationale behind the preference of Direct Acting Oral Anticoagulants (DOACs) over vitamin K antagonists (VKAs) in this specific clinical scenario. Conclude the answer with an adjusted dosage table and a list of bleeding warning signs that the patient should closely monitor during the transition of therapies.